欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (1): 59-64.doi: 10.12092/j.issn.1009-2501.2018.01.012

• 定量药理学 • 上一篇    下一篇

正态资料下采用α'调整作为国际多中心临床试验目标区有效性研究的桥接方法

尚 峰1,虞成凯2,杨 鹏3   

  1. 1 解放军第94医院,南昌 330002,江西; 2 解放军73867部队,九江 332000,江西; 3 第四军医大学卫生统计学教研室,西安 710032,陕西
  • 收稿日期:2017-06-16 修回日期:2017-07-23 出版日期:2018-01-26 发布日期:2018-02-07
  • 通讯作者: 杨鹏,男,博士,副教授,主要从事卫生统计学研究。 Tel:029-84772180 E-mail:fmmuyp@163.com
  • 作者简介:尚峰,男,硕士,主要从事临床管理工作。 Tel:0791-88848114 E-mail:155080@qq.com
  • 基金资助:

    陕西省自然科学基金青年人才项目(2014JM26125)

Bridging method of adjusted significance levels α' in the target region concerning superiority design for normal data distribution in MRCT

SHANG Feng 1, YU Chengkai 2, YANG Peng 3   

  • Received:2017-06-16 Revised:2017-07-23 Online:2018-01-26 Published:2018-02-07

摘要:

目的: 探讨新药在国际多中心临床试验(MRCT)中,以正态资料为主要疗效终点、目标区采用调整后的检验水准α'作为决策依据方法的可行性和α'的合理取值,确定目标区样本量的比例,为MRCT在目标区通过审批提供参考。方法: 利用Monte Carlo法模拟优效性设计和目标区不同规模MRCT的数据模型,在检验水准α=0.05水平上显示试验组优于对照组的前提下,目标区采用调整后检验水准α'作为决策依据的条件Ⅰ型错误率(CFPR)、条件检验效能(CP)随目标区样本量占MRCT样本量占比K的变化情况。结果: 目标区CFPR和CP随着α'的增加而增加,K值越大,相应的目标区CFPR也越高。当K<30%和α'<0.5时,基本可以控制目标区CFPR不超过0.5;当K≤15%和α'=0.5时,即使f=1.0,CP依然很低不足0.76;当K=20%,如果f>0.8,则目标区CP可超过0.70;当K=25%,如果f>0.8,目标区CP可超过0.75;当K=30%,只要f=0.7,目标区CP就能维持在0.80以上;当K=50%时,f即使只有0.5,目标区CP依然可以达到0.80以上。结论: 本研究提出的方法容易理解,便于操作,尤其对于f≥0.7的情形有较好表现。

关键词: 条件Ⅰ型错误, 条件检验效能, 国际多中心临床试验, Monte Carlo模拟

Abstract:

AIM: To explore the feasibility to adjust the significance levels α' in the target region as the basis of data in normal distribution for the primary efficacy endpoint, the reasonable value of adjusted significance levels α' and reasonable proportions of sample size in target region,and to make a reference for new drug approvals of Multi-Regional Clinical Trial (MRCT) in target region.  METHODS: By using Monte Carlo simulation, we studied the conditional false positive rate (CFPR) and conditional power (CP) changing with the proportions K of the sample size in target region by adopting different significance levels given that the treatment effect was shown to be significant under the significance level α=0.05 based on different sized MRCTs. RESULTS:Simulations results showed that CFPR and CP increased with the increasing significance level α' and the bigger K, the bigger CFPR. In addition, CFPR could be well controlled under 0.5 if K was no more than 30% and α' is no more than 0.5. Though f values 1.0, CP still kept low and was no more than 0.76 when K was no more than 15%. If f could be more than 0.8, CP would exceed 0.70 when K valued 20%. If f can be more than 0.8, CP will exceed 0.75 when K values 25%. When K valued 30%, CP would exceed 0.80 as long as f≥ 0.7. Lastly, even though f valued only 0.5, CP would exceed 0.80 when K valued 50%. CONCLUSION: The method in this study is easy to understand and operate, and have a better performance especially when f≥0.7.

Key words:  conditional false positive rate, conditional power, multi-regional clinical trial, Monte Carlo simulation

中图分类号: